Chi-Med Enters into Multiple Collaborations to Evaluate Combinations of Surufatinib and Fruquintinib with PD-1 Checkpoint Inhibitors
Chi-Med Announces Phase III FALUCA Trial Results for Fruquintinib in Third-Line, Advanced Non-Small Cell Lung Cancer in China
Chi-Med Initiates a Phase I Trial of HMPL-523 in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia in China
Chi-Med Announces the Approval of Fruquintinib Capsules for Previously Treated Colorectal Cancer in China
QIMC Further Derisks Nova Scotia Natural Hydrogen Multi-Gas System with New Thermogenic Gas and Helium Results
Flow Metals Secures Little Gold Creek Headwaters, Completing Strategic Consolidation of Sixtymile Gold District
Highlights Include Iron Values Exceeding 30%, Nickel up to 500 ppm, Cobalt up to 187 ppm and Vanadium up to 1,710 ppm
